The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|September 24, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
- Volume 11
- Issue 10
Cobra Biologics Announces Scale-Up Collaboration
Author(s)Pharmaceutical Technology Editors
Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.
Advertisement
Cobra Biologics and Alan Dickson, professor of biotechnology at The University of Manchester (UoM) announced on Sept. 24, 2015 a two-year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported through the FLexible Interchange Programme (FLIP) Scheme from the Biotechnology and Biological Sciences Research Council (BBSRC).
The partnership will address the need for greater predictability and certainty in process development and scale-up for the production of protein-based biopharmaceuticals for application in therapeutic areas including cancer and inflammation, according to a Cobra Biologics press announcement.
The agreement will give Cobra access to the UoM’s academic and associated research group. Professor Dickson will have access to Cobra’s production data and operational knowledge of industrial manufacturing processes. Financial terms and terms relating to IP have not been disclosed.
Source:
Articles in this issue
about 11 years ago
Cost Inhibits CMO Adoption of Single-Use Equipmentabout 11 years ago
Low Temperature Needed for Complex Drug Candidatesabout 11 years ago
FDA Plans Pilot Projects for Drug Supply Chain Security Actabout 11 years ago
Vetter Embarks on 300-Million Euro Manufacturing Expansionabout 11 years ago
Sterigenics International Adds Capacityabout 11 years ago
Tecnandina’s Ecuador Facility Receives ANVISA Certificationabout 11 years ago
Hovione Expands Drug Substance Manufacturingabout 11 years ago
Piramal Introduces Proof of Concept Service for Next Wave of ADC Growthabout 11 years ago
Patheon Unveils New Brand Identityabout 11 years ago
FDA Releases Guidance on Generic-Drug DevelopmentAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement